Positron emission tomography

Show results for

Unknown (9483)
Genomics (71)
Transcriptomics (65)
Clinical (42)
Proteomics (10)
Methylation profiling (4)
Other (2)
Metabolomics (2)
Genomic (1)

Organisms

Homo sapiens (43)
Mus musculus (22)
Andropogon gerardi (7)
Bacteria (7)
Canis lupus familiaris (7)
Clostridium perfringens (7)
Cnidaria (7)
Cricetulus griseus (7)
Eukaryota (7)
Fasciola (7)
Hepatitis B virus (7)
Human betaherpesvirus 5 (7)
Madurella mycetomatis (7)
Mesocricetus auratus (7)
Miscanthus x giganteus (7)
Mus musculus (7)
Mycobacterium tuberculosis (7)
Orthoflavivirus (7)
Panicum virgatum (7)
Platyhelminthes (7)
Pseudomonas aeruginosa AES-1R (7)
Rattus norvegicus (7)
Rattus rattus (7)
Saccharomyces cerevisiae (7)
Schizosaccharomyces pombe (7)
Severe acute respiratory syndrome coronavirus 2 (7)
Sorghastrum nutans (7)
Rattus norvegicus (4)
Macaca fascicularis (2)
Escherichia coli (1)

Organisms

Homo sapiens (39)
Mus musculus (18)
Rattus norvegicus (3)
Macaca fascicularis (2)
mouse gut metagenome (1)

Repository

ENA (71)
geo (51)
biostudies-arrayexpress (20)
pride (7)
MassIVE (2)
MetaboLights (2)
dbGaP (1)
iProX (1)

Tissue

Cardiac muscle cell (2)
Cell culture (2)
Heart (2)
Aorta (1)
Liver (1)
Neuron (1)

Disease

Colorectal Neoplasms (19)
Neoplasm Metastasis (3)
Neoplasms (3)
Rectal Neoplasms (2)
Adenocarcinoma (1)
Metastatic colorectal cancer receiving third-line therapy with cetuximab (1)
Carcinoid Tumor (1)
Brain Neoplasms (1)
Cancer-Bowel-Back passage (rectum) or large bowel (colon) (1)
Colorectal Liver Metastases (1)
Breast cancer (1)
Anal Cancer (1)
Cancer (1)
Surgery Upper Gastro-Intestinal Cancer (1)
Colon cancer (1)
Pancreatic Neoplasms (1)
Carcinoma (1)
Stomach Neoplasms (1)
Intestinal Neoplasms (1)
Atherosclerosis (1)
Cardiomyopathy (1)
Frontotemporal dementia (1)

Technology Type

Mass Spectrometry (7)
Shotgun proteomics (4)
Mass spectrometry (2)
Bottom-up proteomics (2)
Data-independent acquisition (1)

Instrument Platform

Orbitrap Fusion Lumos (1)
Q Exactive Plus (1)
Gas Chromatography MS - (1)
Gas Chromatography MS - positive (1)
Liquid Chromatography MS - (1)

Publication Date

2024 (13)
2023 (9)
2026 (8)
2019 (6)
2025 (6)
2015 (5)
2018 (4)
2008 (4)
2020 (4)
2012 (3)
2021 (3)
2017 (3)
2016 (2)
2014 (2)
2013 (2)
2011 (2)
2007 (2)
2022 (2)
2010 (1)
2006 (1)

CHEBI ID

CHEBI:22605 (2)
CHEBI:22470 (2)
CHEBI:24266 (2)
CHEBI:28822 (2)
CHEBI:32365 (2)
CHEBI:16113 (2)
CHEBI:29019 (2)
CHEBI:48430 (2)
CHEBI:26271 (2)
CHEBI:18237 (2)
CHEBI:15356 (2)
CHEBI:22653 (2)
CHEBI:26986 (2)
CHEBI:17234 (2)
CHEBI:18257 (2)
CHEBI:25017 (2)
CHEBI:28875 (2)
CHEBI:28842 (2)
CHEBI:15428 (2)
CHEBI:16958 (2)
CHEBI:17268 (2)
CHEBI:6650 (2)
CHEBI:28044 (2)
CHEBI:17497 (2)
CHEBI:16196 (2)
CHEBI:18211 (2)
CHEBI:16449 (2)
CHEBI:15843 (2)
CHEBI:16704 (2)
CHEBI:17964 (2)

Metabolite Name

Palmitoleic acid (2)
Palmitic acid (2)
Myristic acid (2)
Uric acid (2)
Xanthine (2)
Hydroxyoctadecanoic acid (1)
Beta-Hydroxytetradecanoic acid (1)
3-OH Dodecanoic acid (1)
Beta-Hydroxybutyric acid (1)
N-Eicosanoic acid (1)
L-2-aminobutyric acid (1)
Hydroxyacetic acid (1)
Fumurate (1)
Erythro-Pentonic acid (1)
Alpha-Amino isobutyric acid (1)
5-hydroxy-2-piperidinecarboxylic acid (1)
4-Methylpentanoic acid (1)
3-hydroxy-3-methyl-butanoic acid (1)
3,6-Dihydroxy-pyrazine (1)
2-oxo-4-methylvaleric acid (1)
2-Oxo-3-methylpentanoic acid (1)
2-Ketoisocaproic acid (1)
2,4-bishydroxybutanoic acid (1)
2,4-bishydroxy-5-hydroxymethyl-Pyrimidine (1)
2,3-Dihydroxybutanoic acid (1)
Linolic acid (1)
Glycerol phosphate (1)
Eicosatrienoic acid (1)
MG(18:2) (1)
Eicosatetraenoic acid (1)

First Public Date

2024 (15)
2023 (10)
2025 (9)
2026 (8)
2014 (7)
2020 (5)
2019 (4)
2022 (3)
2021 (3)
2018 (3)
2017 (2)
2015 (2)

Study status

Completed (21)
Terminated (5)
Recruiting (5)
Active, not recruiting (3)
Withdrawn (3)
Not provided (3)
Not yet recruiting (2)

Study type

Interventional (34)
Transcription profiling by array (17)
Observational (8)
One-color microarray (1)
Comparative genomic hybridization by array (1)
MicroRNA profiling by array (1)

Release Date

2022 (1107)
2021 (1064)
2025 (1044)
2023 (1040)
2024 (983)
2020 (895)
2019 (643)
2018 (634)
2017 (460)
2016 (389)
2015 (316)
2014 (239)
2026 (154)
2013 (144)
2012 (120)
2011 (89)
2010 (63)
2009 (49)
2008 (34)
2007 (13)
2006 (8)
2004 (4)
2005 (3)
2000 (3)
2002 (2)
2001 (2)
2003 (1)

Lab affiliation

Biomolecular characterization unit, Center for Sustainable Resource Science, RIKEN (1)
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) (1)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (1)
Department of Radiology Charité - Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin Germany (1)
Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark (1)
Paris Cardiovascular Research Center (PARCC); INSERM UMR970; Université Paris Descartes; Paris, France (1)
Pharmaceutical Sciences - TTB Roche Pharma Research and Early Development Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Building/Room 93/4.44 Grenzacherstrasse 124 CH-4070 Basel, Switzerland (1)

Location

United States (14)
Netherlands (5)
Australia (5)
Canada (4)
France (3)
Taiwan (2)
Belgium (2)
United Kingdom (2)
Hong Kong (1)
China (1)
South Korea (1)
Germany (1)

Keyword

Fluorodeoxyglucose F18 (6)
PET (4)
Positron emission tomography (3)
Bevacizumab (3)
Cetuximab (3)
Computed tomography (2)
Capecitabine (2)
89Zr (1)
89Zr-DFO-nimotuzumab (1)
Immunohistochemistry, (1)
Monoclonal antibodies, (1)
Predictive model, (1)
Antiangiogenic agents, (1)
Medical imaging (1)
Positron Emission Tomography (PET) (1)
Diagnostic Investigation (1)
Colorectal cancer stage II and III (1)
Metabolic activity (1)
5fluorouracil (1)
FDG-PET-CT (1)
MRS, (1)
Colorectal cancer with histologically proven distant metastases (1)
Pinaverium (1)
Fluorodeoxyglucose (1)
Pinaverium bromide (1)
Telbivudine (1)
FLT-PET (1)
Proliferation markers (1)
Colorectal cancer with liver metastases (1)
Stage I hypopharyngeal cancer (1)

Previous page
1 / 968
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 968
Next page

Sort by:

Relevance

Page size

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

Fluorine-18-fluoro-2-deoxy-D-glucose (FDG) is widely used as positron-emission-tomography (PET) radiotracer for the detection and staging of human cancer. Tumor uptake of FDG varies substantially between different cancer types and between patients with the same tumor type. The molecular basis for th...

ORGANISM(S): Homo sapiens

2011-11-01 | E-GEOD-21217 | biostudies-arrayexpress

Integration of whole-body [18F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes

Alteration of various metabolites has been linked to type 2 diabetes (T2D) and insulin resistance. However, identifying significant associations between metabolites and tissue-specific phenotypes requires a multi-omics approach. In a cohort of 42 subjects with different levels of glucose tolerance (...

2020-01-06 | MTBLS1051 | MetaboLights

Genomic signature of the standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography in breast cancer

PRJNA544730 | ENA

Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Not available

S-EPMC2713098 | biostudies-literature

A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.

Not available

S-EPMC6532410 | biostudies-literature

Estradiol modulates neural response to conspecific and heterospecific song in female house sparrows: An in vivo positron emission tomography study.

Not available

S-EPMC5568339 | biostudies-literature